Moberg Pharma (Sweden)

company in Bromma, Sweden

MOB Nasdaq Stockholm ISIN SE0020353928 LEI 549300XFXK7DVGDRP410
Follow Moberg Pharma (Sweden) Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 SEK · IFRS
Revenue, last year SEK 13.5M +38% vs prior year
Net income −SEK 27.2M +89.3% vs prior year
EPS, diluted −SEK 0.58 +91.4% vs prior year
Operating cash flow −SEK 17.5M −6.2% vs prior year
Revenue by fiscal year
SEK 0
SEK 207K
SEK 0
SEK 9.8M
SEK 13.5M
FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−SEK 300M−SEK 200M−SEK 100MSEK 0SEK 100MFY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25SEK 13.5M−SEK 27.2M
FY24SEK 9.8M−SEK 255.1M
FY23SEK 0−SEK 21.1M
FY22SEK 207K−SEK 15.7M
FY21SEK 0SEK 7.5M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−10000%−7500%−5000%−2500%0%2500%FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2556.7%−201.8%−201.2%
FY2464.4%−3310.9%−2600.3%
FY23---
FY22100%−9771%−7589.4%
FY21---